Otenabant (CP-945,598) is a drug that acts as a potent and highly selective CB₁

antagonist An antagonist is a character in a story who is presented as the main enemy or rival of the protagonist and is often depicted as a villain.Pfizer Pfizer Inc. ( ) is an American Multinational corporation, multinational Pharmaceutical industry, pharmaceutical and biotechnology corporation headquartered at The Spiral (New York City), The Spiral in Manhattan, New York City. Founded in 184 ...

for the treatment of

obesity Obesity is a medical condition, considered by multiple organizations to be a disease, in which excess Adipose tissue, body fat has accumulated to such an extent that it can potentially have negative effects on health. People are classifi ...

, but development for this application has been discontinued following the problems seen during clinical use of the similar drug

rimonabant Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious psychiatric side effects; it was never approved in the United State ...

References

Cannabinoids Purines Piperidines Carboxamides Drugs developed by Pfizer CB1 receptor antagonists 2-Chlorophenyl compounds 4-Chlorophenyl compounds {{cannabinoid-stub

See also

References